Medical biotechnology is a fascinating field that sees stunning breakthroughs year on year. When it comes to the future of medicine and healthcare, successful clinical trials are at the forefront of testing and examining how humans can improve treatment for disease and illness. Here are some of the most exciting breakthroughs from last year:
- PD-L1 Cancer Drug
A drug called Tecentriq has achieved outstanding results in its Phase III clinical trials. It has since been approved for use in metastatic non-small cell lung cancer and bladder cancer. It is unique in that it’s the only rug on the market to specifically target the checkpoint inhibitor Program-Death ligand 1 (PD-L1). The company behind the manufacture of the product hope to soon add colorectal, breast and prostate cancer to its treatment list.
There has long been a desire to find a cure for HIV and one of the most recent hopeful results is the drug Abivax. It contains a small molecule that works to prevent the replication of the HIV virus. Unlike current drugs available for HIV, this drug works where the virus lurks in the body in its latent form. Abivax has the potential to be able to eliminate the virus completely from the body. Successful Phase IIa trials have taken place. For more information on Adaptive Phase 1 Clinical Studies, visit Richmond Pharmacology
- Peanut Allergy
This scary allergy can be deadly for many, with the tiniest amount of peanut needed to cause a highly extreme reaction. Excellent Phase IIb trial results have been announced for a product called Viaskin Peanut. It consists of an easy to apply, comfortable skin patch that vastly improves the symptoms of a peanut allergy attack in young children at risk of death. This skin patch could save many lives from accidental peanut exposure.
- Diagnostic Test for Chemotherapy Need
This ingenious tool is called Mammaprint and was actually released in 2004. Recent studies have shown it may have another equally important role in testing the activity of 70 genes involved in breast cancer and finding out if chemotherapy is indeed the best course of action for a patient. Results from Phase III trials have shown that the need for chemotherapy can be reduced by a whopping 46%. Imagine all those people who could avoid the time, expense and huge health toll that chemo brings.
- Cannabinoids for Epilepsy
A cannabinoid called Epidiolex has been successfully used to reduce the frequency of drug-resistant epileptic seizures in children. These results have been seen in strong Phase III trials for the treatment of Dravet and Lennox-Gastaut Syndrome. Approval is eagerly anticipated and this will be seen as a major advance for the cause of supporters for legalising cannabis.